Home Safety Checklist
RSS Feed Print
Magazines Focusing on Work to Combat AD
Posted: Thursday, March 1, 2012 2:59 PM
Joined: 12/6/2011
Posts: 3326

From Alzheimer's Daily News:

(Source: SmallCap Network) - Recent front page articles in popular magazines, such as Barron's and American Profile, highlight the importance of work on Alzheimer's Disease.

This was emphasized in the cover article in Barron's, "The Fight Against Alzheimer's: Is Hope Near?" The size of the market for a products to combat Alzheimer's Disease is massive. According to the article, "Some think a successful treatment or treatments for Alzheimer's could generate $10 billion to $20 billion in annual revenue.

There are a number of promising products in development. Eli Lilly has a drug called Solanezumab. Pfizer has a product called Bapineuzumab. Anavex has ANAVEX 2-73 for the treatment of Alzheimer's Disease and has successfully completed a Phase 1a Clinical Trial.

The data from the Anavex trial has been published by world-renowned Alzheimer's Disease scientists. It reveals that, according to a previous article, "... ANAVEZ 2-73 exhibits neuroprotective activity and reverses symptoms of AD in mouse models of the disease. Phase 1a clinical data indicates that ANAVEX 2-73 is well tolerated with no dose-limiting toxicities unrelated to the drug's mechanism of action. ANAVEX 2-73 is the first of a new class of oral drugs being studied to potentially treat Alzheimer's through disease modification rather than symptomatic improvement alone."

This was emphasized in the conclusion of the Barron's piece concluded, "[The] ...optimistic scenario for bapiineuzumab and solanezumab is that they can slow its [Alzheimer's] fatal progression, not cure patients. But even that would be good news for the millions of victims of the disease, not to mention the shareholders of the companies behind the medication."

Go to full story: http://www.smallcapnetwork.com

× Close Menu